Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660

Article  PubMed  Google Scholar 

Chiec L, Kumthekar P (2022) Targeting HER2+ breast cancer brain metastases: a review of brain-directed HER2-directed therapies. CNS Drugs 36(2):167–179. https://doi.org/10.1007/s40263-021-00894-x

Article  CAS  PubMed  Google Scholar 

Sanchez-Covarrubias L, Slosky LM, Thompson BJ, Davis TP, Ronaldson PT (2014) Transporters at CNS barrier sites: obstacles or opportunities for drug delivery? Curr Pharm Des 20(10):1422–1449. https://doi.org/10.2174/13816128113199990463

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pearl LH, Schierz AC, Ward SE, Al-Lazikani B, Pearl FM (2015) Therapeutic opportunities within the DNA damage response. Nat Rev Cancer 15(3):166–180. https://doi.org/10.1038/nrc3891

Article  CAS  PubMed  Google Scholar 

Wu L, Zhu J, Yin R, Wu X, Lou G, Wang J, Gao Y, Kong B, Lu X, Zhou Q, Wang Y, Chen Y, Lu W, Li W, Cheng Y, Liu J, Ma X, Zhang J (2021) Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort. Gynecol Oncol 160(1):175–181. https://doi.org/10.1016/j.ygyno.2020.10.005

Article  CAS  PubMed  Google Scholar 

Wang XW, Hu N, Cui L, Si Y, Yue J, Zheng F, Kang Y, Yuan P (2022) Durable disease-free survival in a patient with metastatic triple-negative breast cancer treated with olaparib monotherapy. Curr Cancer Drug Targets. https://doi.org/10.2174/1568009622666220214092207

Article  PubMed  PubMed Central  Google Scholar 

Zhang L, Wang J, Cui LZ, Wang K, Yuan MM, Chen RR, Zhang LJ (2021) Successful treatment of refractory lung adenocarcinoma harboring a germline BRCA2 mutation with olaparib: a case report. World J Clin Cases 9(25):7498–7503. https://doi.org/10.12998/wjcc.v9.i25.7498

Article  PubMed  PubMed Central  Google Scholar 

He JX, Wang M, Huan XJ, Chen CH, Song SS, Wang YQ, Liao XM, Tan C, He Q, Tong LJ, Wang YT, Li XH, Su Y, Shen YY, Sun YM, Yang XY, Chen Y, Gao ZW, Chen XY, Xiong B, Lu XL, Ding J, Yang CH, Miao ZH (2017) Novel PARP1/2 inhibitor Mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution. Oncotarget 8(3):4156–4168. https://doi.org/10.18632/oncotarget.13749

Article  PubMed  Google Scholar 

Nie D, Dai Z, Li J, Yang Y, Xi Z, Wang J, Zhang W, Qian K, Guo S, Zhu C, Wang R, Li Y, Yu M, Zhang X, Shi X, Gan Y (2020) Cancer-cell-membrane-coated nanoparticles with a yolk-shell structure augment cancer chemotherapy. Nano Lett 20(2):936–946. https://doi.org/10.1021/acs.nanolett.9b03817

Article  CAS  PubMed  Google Scholar 

Langen UH, Ayloo S, Gu C (2019) Development and cell biology of the blood-brain barrier. Annu Rev Cell Dev Biol 35:591–613. https://doi.org/10.1146/annurev-cellbio-100617-062608

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gupta A, Chatelain P, Massingham R, Jonsson EN, Hammarlund-Udenaes M (2006) Brain distribution of cetirizine enantiomers: comparison of three different tissue-to-plasma partition coefficients: K(p), K(p, u), and K(p, uu). Drug Metab Dispos 34(2):318–323. https://doi.org/10.1124/dmd.105.007211

Article  CAS  PubMed  Google Scholar 

Hammarlund-Udenaes M, Paalzow LK, de Lange EC (1997) Drug equilibration across the blood-brain barrier–pharmacokinetic considerations based on the microdialysis method. Pharm Res 14(2):128–134. https://doi.org/10.1023/a:1012080106490

Article  CAS  PubMed  Google Scholar 

Hussain A, Altamimi MA, Afzal O, Altamimi ASA, Ali A, Ali A, Martinez F, Mohd Siddique MU, Acree WE Jr, Jouyban A (2022) Preferential solvation study of the synthesized aldose reductase inhibitor (SE415) in the PEG 400 (1) + water (2) cosolvent mixture and gastroplus-based prediction. ACS Omega 7(1):1197–1210. https://doi.org/10.1021/acsomega.1c05788

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng H, Yu J, Yang C, Zhang N, Fan Z, Zhang X, Wang J, Wang Z, Zhong DF, He JX, Yan S, Diao X (2022) Absorption, distribution, metabolism, and excretion of [(14)C]TPN729 after oral administration to rats. Xenobiotica 52(1):79–90. https://doi.org/10.1080/00498254.2022.2030504

Article  CAS  PubMed  Google Scholar 

Tian J, Lei P, He Y, Zhang N, Ge X, Luo L, Yan S, Diao X (2021) Absorption, distribution, metabolism, and excretion of [(14)C]NBP (3-n-butylphthalide) in rats. J Chromatogr B Analyt Technol Biomed Life Sci 1181:122915. https://doi.org/10.1016/j.jchromb.2021.122915

Article  CAS  PubMed  Google Scholar 

Zheng Y, Zhang H, Liu M, Li G, Ma S, Zhang Z, Lin H, Zhan Y, Chen Z, Zhong D, Miao L, Diao X (2021) Pharmacokinetics, mass balance, and metabolism of the novel URAT1 inhibitor [(14)C]HR011303 in humans: metabolism is mediated predominantly by UDP-glucuronosyltransferase. Drug Metab Dispos 50(6):798–808. https://doi.org/10.1124/dmd.121.000581

Article  CAS  PubMed  Google Scholar 

Poulin P, Theil FP (2000) A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci 89(1):16–35. https://doi.org/10.1002/(SICI)1520-6017(200001)89:1%3c16::AID-JPS3%3e3.0.CO;2-E

Article  CAS  PubMed  Google Scholar 

Poulin P, Theil FP (2002) Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 91(1):129–156. https://doi.org/10.1002/jps.10005

Article  CAS  PubMed  Google Scholar 

Poulin P, Theil FP (2002) Prediction of pharmacokinetics prior to in vivo studies II generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci 91(5):1358–1370. https://doi.org/10.1002/jps.10128

Article  CAS  PubMed  Google Scholar 

Diao XX, Zhong K, Li XL, Zhong DF, Chen XY (2015) Isomer-selective distribution of 3-n-butylphthalide (NBP) hydroxylated metabolites, 3-hydroxy-NBP and 10-hydroxy-NBP, across the rat blood-brain barrier. Acta Pharmacol Sin 36(12):1520–1527. https://doi.org/10.1038/aps.2015.64

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu J, Zhang H, Zhang Y, Zhan Y, Ma S, Hu T, Zhang N, Lou Y, Bao H, Xu Z, Zhong D, Miao L, Diao X (2022) Absorption, metabolism, and excretion of [(14)C]YY-20394, a highly selective PI3K-Delta inhibitor in humans. Xenobiotica 52(3):254–264. https://doi.org/10.1080/00498254.2022.2062581

Article  CAS  PubMed  Google Scholar 

Zhou X, Sedarati F, Faller DV, Zhao D, Faessel HM, Chowdhury S, Bolleddula J, Li Y, Venkatakrishnan K, Papai Z (2021) Phase I study assessing the mass balance, pharmacokinetics, and excretion of [(14)C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors. Invest New Drugs 39(2):488–498. https://doi.org/10.1007/s10637-020-01017-x

Article  CAS  PubMed  Google Scholar 

Steensma DP, Wermke M, Klimek VM, Greenberg PL, Font P, Komrokji RS, Yang J, Brunner AM, Carraway HE, Ades L, Al-Kali A, Alonso-Dominguez JM, Alfonso-Pierola A, Coombs CC, Deeg HJ, Flinn I, Foran JM, Garcia-Manero G, Maris MB, McMasters M, Micol JB, De Oteyza JP, Thol F, Wang ES, Watts JM, Taylor J, Stone R, Gourineni V, Marino AJ, Yao H, Destenaves B, Yuan X, Yu K, Dar S, Ohanjanian L, Kuida K, Xiao J, Scholz C, Gualberto A, Platzbecker U (2021) Phase I first-in-human dose escalation study of the oral SF3B1 modulator H3B–8800 in myeloid neoplasms. Leukemia 35(12):3542–3550. https://doi.org/10.1038/s41375-021-01328-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zheng YD, Zhang H, Zhan Y, Bian YC, Ma S, Gan HX, Lai XJ, Liu YQ, Gong YC, Liu XF, Sun HB, Li YG, Zhong DF, Miao LY, Diao XX (2021) Pharmacokinetics, mass balance, and metabolism of [(14)C]vicagrel, a novel irreversible P2Y12 inhibitor in humans. Acta Pharmacol Sin 42(9):1535–1546. https://doi.org/10.1038/s41401-020-00547-7

Article  CAS  PubMed  Google Scholar 

Loryan I, Reichel A, Feng B, Bundgaard C, Shaffer C, Kalvass C, Bednarczyk D, Morrison D, Lesuisse D, Hoppe E, Terstappen GC, Fischer H, Di L, Colclough N, Summerfield S, Buckley ST, Maurer TS, Friden M (2022) Unbound brain-to-plasma partition coefficient, Kp, uu, brain-a game changing parameter for CNS drug discovery and development. Pharm Res 39(7):1321–1341. https://doi.org/10.1007/s11095-022-03246-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kalvass JC, Maurer TS (2002) Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23(8):327–338. https://doi.org/10.1002/bdd.325

Article  CAS  PubMed  Google Scholar 

Wan H, Rehngren M, Giordanetto F, Bergstrom F, Tunek A (2007) High-throughput screening of drug–brain tissue binding and in silico prediction for assessment of central nervous system drug delivery. J Med Chem 50(19):4606–4615. https://doi.org/10.1021/jm070375w

Article  CAS  PubMed  Google Scholar 

Jusko WJ, Molins EAG, Ayyar VS (2020) Seeking nonspecific binding: assessing the reliability of tissue dilutions for calculating fraction unbound. Drug Metab Dispos 48(10):894–902. https://doi.org/10.1124/dmd.120.000118

Article  CAS  PubMed  PubMed Central  Google Scholar 

Strazielle N, Ghersi-Egea JF (2013) Physiology of blood–brain interfaces in relation to brain disposition of small compounds and macromolecules. Mol Pharm 10(5):1473–1491. https://doi.org/10.1021/mp300518e

Article  CAS  PubMed  Google Scholar 

Budiman T, Bamberg E, Koepsell H, Nagel G (2000) Mechanism of electrogenic cation transport by the cloned organic cation transporter 2 from rat. J Biol Chem 275(38):29413–29420. https://doi.org/10.1074/jbc.M004645200

Article  CAS  PubMed  Google Scholar 

Tega Y, Yamazaki Y, Akanuma SI, Kubo Y, Hosoya KI (2018) Impact of nicotine transport across the blood-brain barrier: carrier-mediated transport of nicotine and interaction with central nervous system drugs. Biol Pharm Bull 41(9):1330–1336. https://doi.org/10.1248/bpb.b18-00134